FDA Approves Vidaza for Rare Pediatric Blood Cancer
- OPACC
- May 24, 2022
- 1 min read
The Food and Drug Administration (FDA) approved Vidaza (azacytidine) for the treatment of pediatric patients with newly diagnosed juvenile myelomonocytic leukemia, a rare blood cancer where certain types of white blood cells do not mature normally.
Comments